Specialties – Page 32

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

By MedXY 09/17/2025

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema

By MedXY 09/17/2025

A recent randomized, double-blind trial demonstrates that oral lamivudine significantly improves visual acuity in patients with center-involved diabetic macular edema, offering a cost-effective and safer alternative to conventional anti-VEGF therapy.

Cardiology news Specialties

Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial

By MedXY 09/17/2025

The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.

Cardiology news Specialties

Paclitaxel-Coated vs Uncoated Devices in Chronic Limb-Threatening Ischaemia: Insights from the SWEDEPAD 1 Trial

By MedXY 09/17/2025

The SWEDEPAD 1 trial evaluated paclitaxel-coated versus uncoated devices for infrainguinal revascularisation in chronic limb-threatening ischaemia, finding no significant reduction in major amputations or mortality over a median 2.7-year follow-up.

Clinical Updates Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

By MedXY 09/17/2025

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Diabetes & Endocrinology news Specialties

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

By MedXY 09/17/2025

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Clinical Updates Diabetes & Endocrinology news Specialties

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

By MedXY 09/17/2025

A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.

Clinical Updates Diabetes & Endocrinology Specialties

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

By MedXY 09/17/2025

Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.

$Pitolisant as Adjunct Therapy for Refractory Restless Legs Syndrome: Insights from a Pilot Study$

Clinical Updates Neurology news Pediatrics Specialties

Pitolisant as Adjunct Therapy for Refractory Restless Legs Syndrome: Insights from a Pilot Study

By MedXY 09/17/2025

This pilot study reveals that adjunctive pitolisant, a histamine-3 inverse agonist, is well tolerated and improves symptom scales in refractory restless legs syndrome, suggesting potential to address daytime consequences with minimal core symptom relief. Controlled trials are warranted.

$Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications$

Clinical Updates news Respiratory Specialties

Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications

By MedXY 09/17/2025

The SOOTHE phase 2b trial demonstrates that camlipixant, a P2X3 antagonist, significantly reduces cough frequency and improves quality of life in refractory chronic cough patients, with a favorable safety profile, supporting its potential as a new therapeutic option.

Clinical Updates Respiratory Specialties

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

By MedXY 09/17/2025

The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.

Clinical Updates Infectious Diseases Respiratory Specialties

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial

By MedXY 09/17/2025

A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.

Critical Care Neurology Specialties

Lung-Protective Mechanical Ventilation in Acute Brain Injury: Insights from the PROLABI Trial

By MedXY 09/17/2025

The PROLABI trial assessed lung-protective ventilation in acute brain injury patients and found no improvement in mortality, ventilator dependency, or ARDS incidence, highlighting the need for further research in this population.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

By MedXY 09/17/2025

Combining aerobic and resistance exercise with diet-induced weight loss in obese older adults significantly improves insulin secretion, preserves CNTFRα levels, and increases IGF-1, enhancing metabolic and physical function.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Hydroxytyrosol Supplementation Enhances Antioxidant and Anti-Inflammatory Status in Overweight Prediabetic Adults: Insights from a Randomized Controlled Trial

By MedXY 09/17/2025

A 16-week randomized trial demonstrates that daily hydroxytyrosol supplementation significantly reduces oxidative stress and inflammatory markers in overweight individuals with prediabetes, highlighting its potential in preventing aging-related diseases.

Neurology news Specialties

Electrical Vestibular Stimulation: A Promising Adjunct Therapy for Adult Insomnia in Hong Kong

By MedXY 09/17/2025

A double-blind, randomized trial demonstrates that electrical vestibular stimulation (VeNS) significantly reduces insomnia severity and improves quality of life in adults, highlighting a novel non-pharmacological treatment option.

Diabetes & Endocrinology news Specialties

Enhancing Cognitive Function in Older Adults with Type 2 Diabetes: The Superior Effects of Tai Chi in a Mobile Health Trial

By MedXY 09/17/2025

This randomized controlled trial demonstrates that Tai Chi, combined with wearable device monitoring in a telemedicine model, significantly improves cognitive function and sleep quality in older adults with type 2 diabetes, outperforming fitness walking and usual care.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Tai Chi and Cognitive Enhancement in Older Adults With Type 2 Diabetes Mellitus: Evidence From Randomized Controlled Trials Using Wearable Technology in mHealth Models

By MedXY 09/17/2025

Emerging RCT evidence supports Tai Chi's superior benefits over fitness walking in improving cognitive function and sleep quality among older adults with type 2 diabetes and mild cognitive impairment, facilitated by telemedicine and wearable devices.

Clinical Updates Family Medicine & Nutrition news Psychiatry Specialties

Add-on Probiotics for Inflammatory Depression: Insights from a Double-Blind Randomized Placebo-Controlled Trial

By MedXY 09/17/2025

This study evaluated the antidepressant effects of a Lactobacillus probiotic in overweight depressed patients with systemic low-grade inflammation, revealing no overall benefit but highlighting fecal formic acid as a potential biomarker for treatment response.

Clinical Updates Family Medicine & Nutrition news Psychiatry Specialties

Enhancing Vagal Nerve Function with Multi-Species Probiotics: A Promising Therapeutic Avenue for Major Depression

By MedXY 09/17/2025

A 3-month RCT demonstrates that multi-species probiotic supplementation improves vagal nerve function, gut microbiome composition, and sleep quality in patients with major depression, suggesting novel gut-brain axis interventions.